ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

H. Lundbeck A/S clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 276 studies whose lead sponsor is H. Lundbeck A/S or one of 10 companies grouped under it. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 13, 2026.

Our grouping of 11 registry names, not the registry’s. See them and correct one ↓

Compare H. Lundbeck with Pfizer and AbbVie →

Pipeline: 6 programs

Each counted once: 6 with a study H. Lundbeck A/S leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 2 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of H. Lundbeck A/S’ own registered studies; H. Lundbeck A/S’ own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs H. Lundbeck A/S’ studies test, most open studies first — 42 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 42; every drug is on its own page, and each page lists its sponsors.

Coming up

7 of H. Lundbeck A/S’ studies under way reach primary completion within a year, 4 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 1D
  3. J’27
  4. 1F
  5. 1M
  6. A
  7. 1M
  8. J
  9. 1J
  10. 1A
  11. S
  12. O
  13. 1N

Add all 7 to your calendar (.ics) → With an account.

All 276 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now104%Recruiting 8 · Not yet recruiting 1 · Enrolling by invitation 1
  • Under way, not recruiting73%
  • Completed20875%
  • Stopped early5018%Terminated 42 · Withdrawn 8
  • Status unknown or other1<1%

Phase

  • Phase 1107
  • Phase 398
  • Phase 245
  • Phase 422
  • Early Phase 11

Where

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 2014
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 426

By the year each study started; 27 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to H. Lundbeck A/S.

  • H. Lundbeck A/S
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    224 studies
  • Chelsea Therapeutics
    Acquired — became part of H. Lundbeck A/S, Jun 23, 2014 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    16 studies →
  • Lundbeck LLC
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    9 studies →
  • Longboard Pharmaceuticals
    Acquired — became part of H. Lundbeck A/S, Dec 2, 2024 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Abide Therapeutics
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Alder Biopharmaceuticals, Inc.
    Acquired — became part of H. Lundbeck A/S, Oct 22, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • Prexton Therapeutics
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Lundbeck Canada Inc.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Saegis Pharmaceuticals
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • Lundbeck Japan K. K.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • Lundbeck Italia S.p.A.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions H. Lundbeck A/S leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 276. Browse all 276 →